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Abstract: One of the major hurdles to porcine reproductive and respiratory syndrome (PRRS)
vaccinology is the limited or no cross-protection conferred by current vaccines. To overcome this
challenge, a PRRS chimeric virus (CV) was constructed using an FL12-based cDNA infectious
clone in which open reading frames (ORFs) 3–4 and ORFs 5–6 were replaced with the two Korean
field isolates K08-1054 and K07-2273,respectively. This virus was evaluated as a vaccine candidate
to provide simultaneous protection against two genetically distinct PRRS virus (PRRSV) strains.
Thirty PRRS-negative three-week-old pigs were divided into five groups and vaccinated with CV,
K08-1054, K07-2273, VR-2332, or a mock inoculum. At 25 days post-vaccination (dpv), the pigs
in each group were divided further into two groups and challenged with either K08-1054 or
K07-2273. All of the pigs were observed until 42 dpv and were euthanized for pathological evaluation.
Overall, the CV-vaccinated group exhibited higher levels of tumor necrosis factor-alpha (TNF-α),
interferon-gamma (IFN-γ), and interleukin-12 (IL-12) expression and of serum virus-neutralizing
antibodies compared with the other groups after vaccination and also demonstrated better protection
levels against both viruses compared with the challenge control group. Based on these results, it
was concluded that CV might be an effective vaccine model that can confer a broader range of
cross-protection to various PRRSV strains.
Keywords: porcine reproductive and respiratory syndrome; chimeric virus; cytokines; serum virus
neutralizing antibodies; vaccine; pig
1. Introduction
More than two decades after its emergence in the United States and Europe, porcine reproductive
and respiratory syndrome (PRRS) continues to be a cause of great concern for swine producers
worldwide. The disease is characterized by stillbirth and abortion in adult pigs and respiratory
disease and mortality in pigs of all ages [1]. The causative agent, porcine reproductive and respiratory
syndrome virus (PRRSV), is a single-stranded positive sense RNA virus (~15 kb) that belongs to the
family Arteriviridaeandorder Nidovirales [2]. PRRSV has a polycistronic genome that consists of two
large open reading frames (ORFs), 1a and 1b, encoding non-structural proteins (nsps) and eight ORFs
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that encode structural proteins [3,4]. ORFs 1a and 1b encode replicase polyproteins 1a (pp1a) and
pp1ab, and translation of the latter occurs due to a ribosomal frame shift towards the C-terminus of
ORF1a. These polyproteins are serially cleaved into at least 14 nsps [5]. ORFs 2a, 3, and 4 encode three
N-glycosylated minor envelope proteins, viz. GP2a, GP3, and GP4, which are linked by disulfide bonds
to form heterotrimers [6]. ORF2b, embedded in ORF2a, encodes a non-glycosylated minor protein [7].
GP5, encoded by ORF5, is a major envelope protein that forms a heterodimer with matrix (M) protein,
which is encoded by ORF6 [8]. This heterodimer recruits other envelope protein heterodimers and
thus plays an important role in virus assembly [6]. Additionally, GP5a has been recently identified
and is encoded by an alternate ORF5 [4]. The nucleocapsid (N) protein is expressed from ORF7 and
contains nuclear localization signals (NLSs) and nuclear export signals (NESs) [9].
Presently, a major drawback in the use of current PRRS modified live vaccines (MLVs) is that
they offer limited to no cross-protection despite conferring solid homologous protection [10–13].
Killed PRRS vaccines have also been previously used, but they offer limited protection against even
homologous viruses [3]. It is now generally accepted that strain-specific vaccines cannot fully protect
against newly emerging PRRSV outbreaks, whereas multi-strain vaccines have shown more severe
clinical signs in pigs [14]. Moreover, owing to the considerable variation between PRRSV strains in
terms of replication efficiency [15], immune response [16], and neutralizing antibody induction [17],
multi-strain vaccines for PRRS have limited potential. Conventional methods used for RNA virus
vaccine development have been successful in the past, but reverse genetics approach might be more
efficient [18]. To date, over 14 infectious clones of type I and type II PRRSV have been developed using
reverse genetics, and this approach can be further utilized to construct safe and efficacious chimeric
vaccines against PRRSV [5,19]. Recently, a study revealed that vaccine chimeras between MN-184
and licensed MLV (Ingelvac® PRRS MLV) attenuated clinical signs in pigs challenged with virulent
viruses [20]. However, to broaden the cross-protective range of vaccine candidates, the chimerization
of multiple PRRSV strains should be attempted to develop a monovalent chimeric vaccine that includes
neutralizing epitopes from genetically diverse PRRSV strains. Therefore, in this study, a chimeric virus
(CV) derived from three genetically diverse strains of PRRSV was constructed and evaluated for its
safety and cross-protective efficacy.
2. Materials and Methods
2.1. Viruses and Cells
VR-2332, a parental virus of MLV (Ingelvac® PRRS MLV, Boehringer Ingelheim, St. Joseph, MO,
USA), which is the most commonly used vaccine in Korea, and two type 2 Korean PRRSV strains,
K08-1054 (Accession number: JQ656266) and K07-2273 (Accession number: JQ656251), were used in
this study. Based on the ORF5 amino acid sequence, K08-1054 and K07-2273 share 85.1% identity,
and FL12 and K08-1054 or K07-2273 share 91% or 88.1% identity, respectively. VR-2332 shares a
high sequence identity (96.5%) with K08-1054 and a low identity (84.6%) with K07-2273, whereas
FL12 and VR-2332 share 90.5% sequence identity (Table 1). MARC-145, an African green monkey
kidney cell line that is highly permissive to PRRSV, was used for virus propagation. MARC-145
cells were maintained in an Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco® RPMI
1640, Life Technologies, Carlsbad, CA, USA) supplemented with heat-inactivated 10% fetal bovine
serum (FBS, Life Technologies), 2 mM L-glutamine, and Antibiotic-Antimycotic 100× (Anti-anti, Life
Technologies) containing 100 IU/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL Fungizone®
(amphotericin B). In this paper, this medium will be referred to as complete RPMI (cRPMI) medium.
The cells were maintained at 37 ◦C in a humidified 5% CO2 incubator.
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2.2. Construction of Chimeric Infectious Clones
FL12 cDNA infectious clone [21] was re-cloned into a vector (pOptiVEC™-TOPO® TA Cloning
kit, Life Technologies) to construct a modified FL12-based infectious clone (pFL12/24) by inserting
FL12 viral sequences between the human cytomegalovirus (CMV) promoter and the internal ribosomal
entry site (IRES) that are present in the vector. Because the modified infectious clone contains the
human CMV promoter and an IRES that initiates transcription and translation of the viral genome,
viruses can be rescued after direct transfection of the infectious clone into MARC-145 cells without
in vitro transcription [19]. Then, the structural genes (ORFs 3–7) including the downstream end of
pFL12/24 ORF2 were cloned into a vector (pGEM®-T Easy vector, Promega Corporations, Madison,
WI, USA) using SphI and SpeI restriction sites to produce an FL12-based structural gene shuttle vector
(sFL3–7). The shuttle vector was used as a template for gene swapping using PCR-based mutagenesis
as described in a previous study [22]. ORFs 3–4 and 5–6 of sFL3–7 were sequentially replaced with
the corresponding ORFs from K08-1054 and K07-2273, respectively, to construct a chimeric shuttle
vector (sFLK3–6). Then, ORFs 1b–3 from pFL12/24 were digested and cloned into the chimeric shuttle
vector using PmeI and BsrGI restriction sites to construct sFL1b-K3–6+. Because a major portion of
ORF3 was duplicated in this chimeric shuttle vector, the 1047 bp region between the HpaI and BsrGI
restriction sites was amplified from pFL12/24 using high-fidelity PCR (GeneAmp® High Fidelity PCR
system, Applied Biosystems®, Life Technologies) to replace the ORF three-repeat region (1813 bps)
in sFL1b-K3–6+ using HpaI and BsrGI restriction sites, which consequently led to the construction of
sFL1b-K3–6. Then, the sequences downstream from ORF 6, including the IRES sequence downstream
of the end of the pFL12/24 poly-A tail, were amplified with high-fidelity PCR (GeneAmp® High
Fidelity PCR system) using the primers listed in Table 1 and were cloned into sFL1b-K3–6 using AflII
and PacI restriction sites, generating sFL1b-K3–6R. ORF1b, the structural genes and the IRES sequence
from sFL1b-K3–6R, were placed in the pFL12/24 backbone to construct the chimeric infectious clone
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Figure 1. Graphical representation of the genomic construct for the chimeric infectious clone (pFLK3–6).
Black, white, and gray arrows represent the open reading frames (ORFs)/gene fragments from
pFL12/24, K08-1054, and K07-2273, respectively. The restriction sites used for cloning are listed
above the construct. CMV: human cytomegalovirus; AflII, BsrGI, HpaI, PacI, PmeI: restriction sites.
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ORF 3 ORF 4 ORF 5 ORF 6
a b c d e a b c d e a b c d e a b c d e
a 94.1 99.6 85.1 88.2 96.6 99.4 66.3 88.3 96.5 85.1 85.1 91.0 98.3 94.9 94.4 96.6
b 5.7 94.1 86.3 87.5 2.8 96.6 65.7 88.8 3.0 84.6 84.6 90.5 1.2 94.9 94.9 97.1
c 0.0 5.7 85.1 88.2 0.0 2.8 66.3 88.3 16.1 16.7 99.5 88.1 4.7 4.7 99.4 94.9
d 16.2 14.7 16.2 83.5 43.6 44.6 43.6 66.9 16.1 16.7 0.0 88.1 4.7 4.7 0.0 94.9
e 12.4 13.3 12.4 18.1 12.1 11.5 12.1 43.6 9.0 9.6 12.4 12.4 2.9 2.3 4.7 4.7
Different letters signify different viruses used in this study (a: K08-1054; b: VR-2332; c: chimeric virus (CV); d: K07-2273; e: FL-12).
Table 2. Primers used in the construction of the chimeric virus.
Primer Name Primers (5′–3′) Sequence Origin Nucleotide Position/Ref. Purpose
SphI/BsrGI-F GCATGCGTGTCAAAGCTTGTACATTCCTCCATATTTTCCTCC Virus [21] Shuttle vector construction
SpeIpolyA-R ACTAGTGTGTCAGTCGACGCGTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTAATTTCGGCCGCATGGTTCTCGC Virus [21] Shuttle vector construction
N_K08-1054_ORF3F TCCTCCATATTCTCCTCTGTT Virus 12,717–12,737 Gene Swap
N_K08-1054_ORF3R TGGTGTTGGTCTCAATGTCTGC Virus 13,336–13,357 Gene Swap
N_K08-1054_ORF4F TTGGTTTCTCAGGCGTTC Virus 13,288–13,305 Gene Swap
N_K08-1054_ORF4R CCCCAACATACTTAAACA Virus 13,781–13,798 Gene Swap
N_K07-2273_ORF5F ATGTTGGGGAAATGCTTGAC Virus 13,790–13,809 Gene Swap
N_K07-2273_ORF5R GAAAACGCCAAAACTACCT Virus 14,426–14,444 Gene Swap
N_K07-2273_ORF6F GTCCCTAGACGACTTTTG Virus 14,385–14,402 Gene Swap
N_K07-2273_ORF6R CTTGCCGTTGTTATTTGG Virus 14,894–14,911 Gene Swap
PmeI-F GGTTTTCCCAGTCACGACGTGTTTAAACGACGGCCAGTGAATTG Vector 2944–2987 Site-Directed Mutagenesis
PmeI-R CAATTCACTGGCCGTCGTTTAAACACGTCGTGACTGGGAAAACC Vector 2944–2987 Site-Directed Mutagenesis
PacI-F CTAATGAGTGAGCTAACTCAGATTAATTAAGATTGGGCTCACTGCC Vector 252–296 Site-Directed Mutagenesis
PacI-R GGCAGTGAGCCCAATCTTAATTAATCTGAGTTAGCTCACTCATTAG Vector 252–296 Site-Directed Mutagenesis
AflII-PacI F CCAAATAACAACGGCAAG Virus 15,665–15,682 Shuttle vector construction
AflII-PacI R ATGAACAAACGACCCAACA Vector † 1319–1337 Shuttle vector construction
HpaI-BsrGI F GATGGTCTGGAAGGACAAG Virus 11,572–11,590 Site-Directed Mutagenesis
HpaI-BsrGI R ATGGAGGAGTGTACAGCTATTAG Virus 12,702–12,724 Site-Directed Mutagenesis
Nucleotide sequences in bold letters represent PRRS virus-specific sequences. Nucleotide sequences in italics represent restriction enzyme recognition sites; † pOptiVEC™-TOPO® TA
cloning kit vector, pGEM®-T Easy vector. F: forward; R: reverse.
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2.3. Generation of Mutant Virus
After confirming the sequence of ORF1b and all of the structural genes, the chimeric infectious
clone pFLK3–6 was transfected into MARC-145 cells. Cells were harvested, washed, and resuspended
in Dulbecco’s modified Eagle medium (DMEM) containing 1.25% dimethyl sulfoxide (DMSO) at
5 × 106 cells/mL. The cells were transfected with 10µg of chimeric infectious clone and were
electroporated at 250 V and 950 µF using an electroporation system (Gene PulserXcell™ Electroporation
System, Bio-Rad Laboratories, Hercules, CA, USA). After electroporation, the cells were diluted in
cell growth medium without antibiotics, seeded into six-well plates (BD Falcon, Franklin Lakes, NJ,
USA) and incubated in a humidified chamber at 37 ◦C and 5% CO2. After 16 h of incubation, the
cells were replenished with cRPMI and incubated under the same conditions for 32 h, after which the
supernatant was collected. The MARC-145 cells seeded in 24-well plates were infected with 0.5 mL of
the supernatant and were incubated under same conditions for up to five days until cytopathic effect
(CPE) was observed in the cells. CV stocks were prepared by passaging supernatants three times in
MARC-145 cells and were stored at −80 ◦C after titration until use. The rescued virus was sequenced,
and the full-length CV sequence was deposited in GenBank (Accession number: KP70428).
2.4. Design for Animal Experiments and Sample Collection
A total of 30 three-week-old PRRS-negative pigs were purchased and randomly assigned to
five groups of six each. Group 1 was mock-treated with RPMI, and groups 2–5 were vaccinated
intramuscularly (IM) with K07-2273, K08-1054, VR-2332, or CV, respectively, using 2 mL of each virus
diluted in RPMI to 103 50% tissue culture infectious dose (TCID50)/mL. At 25 days post-vaccination
(dpv), each group of six pigs was randomly divided into two groups of three and challenged with
either K08-1054 or K07-2273 at a titer of 103 TCID50/mL by the intranasal (IN) route. Serum samples
from all of the pigs were collected every week until 21 dpv, after which they were collected every three
days after virus challenge until 42 dpv or 17 days post-challenge (dpc). Whole blood was collected
at 21 dpv for peripheral blood mononuclear cell (PBMC) isolation. All of the pigs were weighed
at 0 and 25 dpv and euthanized for necropsy at 42 dpv. To evaluate gross and microscopic lung
lesions, each lung lobe was scored for percentage of lung consolidation [23] and interstitial pneumonia,
respectively, caused by PRRSV infection. Scoring for microscopic lung lesions was recorded as
follows: 0, indicates no lesion; 1, mild interstitial pneumonia; 2, moderate multifocal interstitial
pneumonia; 3, moderate diffused interstitial pneumonia; and 4, severe interstitial pneumonia. Lung
tissues were collected from each pig and stored at −80 ◦C until examination. The animal experimental
protocol was approved by the Chonbuk National University Institutional Animal Care and Use
Committee (Approval number: 2012-0025).
2.5. Quantification of PRRSV RNA in Sera and Lungs
Viral RNA was extracted from 100 µL of serum and 1g of lung samples using a viral RNA
extraction kit (MagMAX™ Viral RNA Isolation Kit, Life Technologies) and a total RNA extraction
kit (Hybrid-RTM, GeneAll, Seoul, Korea) according to the manufacturer’s instructions. The virus
levels in serum and lungs were measured using a real-time reverse transcription-polymerase chain
reaction (RT-PCR) employing a one-step reverse transcriptase kit (AgPath-IDTM One-Step RT-PCR Kit,
Ambion, Austin, TX, USA) with the 7500 Fast Real-time PCR system (Applied Biosystems, Foster City,
CA, USA). Primers and aminor groove binder (MGB) fluorescent probe specific to a conserved region
of ORF7 were used as described previously [24].
2.6. Assessment of PRRSV-Specific Antibodies
A fluorescent focus neutralization (FFN)-based serum virus neutralization (SVN) assay was
performed to evaluate SVN antibody titers induced by PRRSVs after vaccination and challenge.
The cross-SVN antibodies induced in vaccinated and challenged groups were evaluated against
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K08-1054 and K07-2273. The SVN assay was performed in MARC-145 cells as described
previously [7,22]. The SVN antibody titer of each anti-serum against each virus was expressed
as the reciprocal of the highest dilution in which 90% or more reduction in the number of fluorescent
focus unit (FFU) was observed compared to the wells of the respective virus back titration.
The presence of PRRSV N-specific antibodies in the sera of vaccinated and virus-challenged
animals was determined using a direct enzyme-linked immune sorbent assay (ELISA) kit
(HerdCheck®PRRS Antibody Kit 3XR, IDEXX Laboratories, Westbrook, ME, USA) according to the
manufacturer’s instructions.
2.7. Isolation of PBMCs
Blood from each pig was collected 21 days after vaccination, and the isolation of porcine peripheral
blood mononuclear cells was performed using the density gradient method in Histopaque-1077®
solution (Sigma, St. Louis, MO, USA) from 5mL blood samples collected in lithium-heparin-containing
vacutainers according to the manufacturer’s instructions. The blood samples were briefly stratified on
Histopaque-1077® solution at a ratio of 1:1 (blood: Histopaque) and centrifuged at 400× g for 30 min.
The purified PBMCs were collected and washed twice with sterile phosphate buffered saline (PBS)
(pH 7.0) supplemented with 1% FBS (Gibco, Carlsbad, CA, USA) and were resuspended in 0.5 mL
of sterile PBS. To evaluate viability and number, the cells were diluted 100 times in PBS, mixed with
0.4% Trypan blue at a 1:1 ratio, and counted using a Countess™ Automated Cell Counter (Invitrogen,
Carlsbad, CA, USA). The cells were diluted to 1 × 106 cells/mL in cRPMI, and 1 mL of cells per
well were seeded in 24-well plates (BD Falcon, Franklin Lakes, NJ, USA) and incubated at 37 ◦C in a
humidified 5% CO2 incubator for 72 h.
2.8. Cytokine mRNA Quantification by Real-time RT-PCR
PBMCs were harvested at 72 h, and cellular RNA was extracted using an RNA isolation kit
(GeneAll® Hybrid-RTM kit, GeneAll Biotechnology, Seoul, Korea) following the manufacturer’s
instructions. RNA was reverse-transcribed into complementary DNA (cDNA) using a high-capacity
cDNA reverse transcription kit (Applied Biosystems) following the manufacturer’s instructions.
Real-time RT-PCR was performed on a 7500 Fast Real-time PCR system (Applied Biosystems) using
various cytokine-specific primers according to the manufacturer’s instructions. Sequences of the
primers used in this study are shown in Table 3. Ten microliters of 2× Power SYBGR (Applied
Biosystems), 2 µL cDNA, and 1 µL each of the forward primer (10 pmol/µL) and reverse primer
(10 pmol/µL) were used for PCR amplification. All of the samples were tested in duplicate, and the
cycling conditions were as follows: (a) 10 min at 95 ◦C; (b) 40 cycles of 15 s at 95 ◦C and 1 min at 60 ◦C;
and (c) melt curve stage for 15 s at 95 ◦C, 1 min at 60 ◦C, 15 s at 95 ◦C, and 15 s at 60 ◦C. Relative
quantities of cytokine mRNA in infected and non-infected cells were normalized to β-actin mRNA,
and the amounts were determined using the 2−∆∆Ct method [25].
Table 3. Primers used to measure the mRNA expression levels of various cytokines.
Genes Forward Primer (5′–3′) Reverse Primer (5′–3′) * Accession/Ref.
β-Actin GCGGGACATCAAGGAGAAG AGGAAGGAGGGCTGGAAGAG U07786
TNF-α TTATTCAGGAGGGCGAGGT AGCAAAAGGAGGCACAGAGG NM214022
IFN-α TCTCATGCACCAGAGCCA CCTGGACCACAGAAGGGA [26]
IL-10 TGACGATGAAGATGAGGAAGAA GAACCTTGGAGCAGATTTTGA NM_214041
IL-12 TCAGGGACATCATCAAACCA GAACACCAAACATCAGGGAAA NM214013
IFN-γ GACTTTGTGTTTTTCTGGCTCTTAC TTTTGTCACTCTCCTCTTTCCA NM_213948
TNF: tumor necrosis factor; IFN: interferon; IL: interleukin; * GenBank Accession number.
2.9. Cytokine Quantification by ELISA
Tumor necrosis factor-α (TNF-α) and interleukin-12 (IL-12) protein levels in sera and PBMC
supernatants were quantified using a commercially available ELISA kit (DuoSet® ELISA, R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s instructions.
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2.10. Sequence and Data Analysis
Graphs were constructed using GraphPad Prism 5.0.2 (GraphPad, San Diego, CA, USA),
and statistical analysis was performed using SPSS Advanced Statistics 17.0 software (SPSS Inc., Chicago,
IL, USA). The Mann-Whitney U test was used to estimate the differences between groups. To prepare
a consensus sequence, the forward and reverse nucleotide sequences were aligned using Seqman™
(DNASTAR Inc., Madison, WI, USA). The consensus sequences of different viruses were aligned
using Lasergene® MegAlign software (DNASTAR Inc.). The phylogenetic tree was generated using a
neighbor-joining method available in the Molecular Evolutionary Genetic Analysis software package,
version 6 (MEGA6) [27].
3. Results
3.1. Safety of Chimeric Vaccine
The mean peak virus titers in all of the vaccinated groups ranged between 103.82 and 104.87
TCID50/mL at 7 dpv, which gradually declined to 100.3–1.0 TCID50/mL at 21 dpv (Figure 2). The CV
showed significantly higher replication in pigs at 7 dpv compared with the other vaccination groups,
reaching a mean peak titer of 104.87 TCID50/mL and decreasing to 100.47 TCID50/mL at 21 dpv.
The other viruses (K08-1054, VR-2332 and K07-2273) reached mean peak titers of 103.82, 104.41 and
104.43 TCID50/mL, respectively, at 7 dpv and gradually declined to 100.31, 101.09 and 100.64 TCID50/mL
at 21 dpv. However, the average daily weight gain (ADWG) was highest in the CV-vaccinated group
when gains were assessed between 0 and 25 dpv to evaluate the effect of the vaccines on pig growth,
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Figure 2. Viral loads in pig serum at 0, 7, 14, and 21 days post-vaccination (dpv). The virus titers were
calculated based on the standard curve of the threshold cycle number plotted against the known virus
titer of VR-2332. The bars represent the means, and the error bars represent the standard errors of the
mean (SEM). Bars showing different letters represent values significantly different from each other
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Figure 3. Effect of virus eplication n pig gro . The ave age daily wei ht gain (ADWG) was
calculated from six pigs in each group at 25 dpv. The bars represent the means, and the error bars
represent the standard errors of the mean (SEM).
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3.2. Cytokine Responses by Chimeric Vaccine Inoculation
The mRNA and protein expression levels of various cytokines were quantified in the PBMCs of
vaccinated pigs (Figure 4). mRNA encoding the regulatory cytokine IL-10 was significantly lower in
the CV-vaccinated group compared to any other group. In contrast, interferon-γ (IFN-γ) and TNF-α
mRNA levels were highest in the CV-vaccinated group among all of the groups and were significantly
higher (p < 0.05) than those of mock-treated control and K08-1054-vaccinated groups. TNF-α protein
levels in the supernatant of PBMC cultures from the CV group were the highest of the groups and
were significantly higher than the mock-treated control group (p < 0.05). There were no significant
differences in IFN-α and IL-12 mRNA levels among the groups, and IL-12 protein levels in the PBMC
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quantitative  real  time  polymerase  chain  reaction  (qRT‐PCR).  Relative  quantification  of  mRNA 
expression  was  estimated  using  the  2−ΔΔCt  method,  and  IL‐12  and  TNF‐αprotein  levels  were 





















































































Figure 4. mRNA and protein expression of cytokines in peripheral blood mononuclear cells (PBMCs)
from vaccinated pigs at 21 dpv. Analysis of interferon-alpha (IFN-α), IFN-γ, interleukin (IL)-10, IL-12,
and tumor necrosis factor-alpha (TNF-α) mRNAs (A–E) and protein (F,G) expression levels of various
cytokines in PBMCs after 72 h culture. Changes in mRNA expression were evaluated by quantitative
real time polymerase chain reaction (qRT-PCR). Relative quantification of mRNA expression was
estimated using the 2−∆∆Ct method, and IL-12 and TNF-αprotein levels were quantified in PBMC
supernatants by ELISA. Bars showing different letters represent values significantly different from each
other (p < 0.05). RQ: Relative Quantification.
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3.3. Antibody Responses after Vaccination and Challenge
Animals in all of the groups except the non-vaccinated group tested positive by IDEXX PRRS
ELISA at 7 dpv (Figure 5). The sample-to-positive (S/P) values in CV-vaccinated pigs were higher
than any other group at 7 dpv and 14 dpv and were significantly higher (p < 0.05) than the S/P values
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significantly different from each other (p < 0.05). 
Based on the virus neutralization test results, pigs inoculated with CV produced approximately 
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Figure 5. Antibody titers of vac inated pigs RS ELISA. The 0.4 S/P ratio represents
the threshold value designated by a dashe li Bars showing diff rent letters represent values
significantly differ nt from each other (p < .
Based on the virus neutralization test results, pigs inoculated with CV produced approximately
2- to 5-fold higher (p ≤ 0.05) SVN antibody titers compared with pigs inoculated with K08-1054,
VR-2332, or K07-2273 against each homologous virus at 21 dpv (Figure 6A). However, no pigs from
either of the inoculated groups produced SVN antibody against heterologous viruses at 21 dpv (data
not shown). The SVN antibody titers in all of the groups were evaluated again 42 dpv after the
virus challenge. The SVN antibody titers induced in CV/K08-1054 were very similar to the SVN
antibody titers induced in the homologous challenge group (K08-1054/K08-1054) (p > 0.05) and
approximately 3- to 6-fold higher than Mock/K08-1054, VR-2332/K08-1054, or K07-2273/K08-1054
against K08-1054 (Figure 6B). Moreover, among the groups challenged with K07-2273, CV/K07-2273
produced the highest SVN antibody titres, which were approximately 3- to 5-fold higher than those of
Mock/K07-2273, K08-1054/K07-2273 or VR-2332/K07-2273 and were also 3-fold higher than those of
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Non‐vaccinated  pigs  challenged  with  K07‐2273  also  developed  acute‐phase  viremia  that 
reached a peak virus titer of 104.50 TCID50/mL at 34 dpv but declined steadily to 103.77 TCID50/mL by 





























Figure 6. Serum virus neutralization (SVN) antibody titers of vaccinated pigs 21 and 42 dpv. SVN
antibody titers of sera collected from pigs vaccinated with K08-1054, VR-2332, CV or K07-2273
against each homologous virus at 21 dpv (A). Virus-neutralizing antibody titer in sera from
K08-1054-challenged groups against K08-1054 at 42 dpv (B) and virus-neutralizing antibody titer
in sera from K07-2273-challenged groups against K07-2273 at 42 dpv (C). Bars showing different letters
represent values significantly different from each other (p < 0.05).
3.4. Viremia Lev ls after Challenge
After non-vaccinated pigs ere c allenged with K08-1054, acute-phase viremia was observed
at 34 dpv ith a peak virus titer of 103.71 that gradually decreased to 102.54 TCID50/mL by 42 dpv.
The homologous challenge (K08-1054/K08-1054) and chimeric virus (CV/K08-1054) groups developed
mild viremia after the challenge that steadily decreased and was nearly resolved at 42 dpv. The other
two heterologous groups (K08-1054/K07-2273 and K08-1054/VR-2332) also developed mild viremia.
However, K08-1054/K07-2273 experienced delayed viremia reduction, whereas there was negligible
virus titer decrease in the K08-1054/VR-2332 group from 28 dpv to 42 dpv (Figure 7A).
Non-vaccinated pigs challenged with K07-2273 also developed acute-phase viremia that reached
a peak virus titer of 104.50 TCID50/mL at 34 dpv but declined steadily to 103.77 TCID50/mL by
42 dpv. The homologous challenge (K07-2273/K07-2273) and the chimeric virus (CV/K07-2273) groups
challenged with K07-2273 displayed a similar pattern of viremia, although there was a slight increase
in t e virus titer in the CV/K07-2273 group at 31 dpv (Figure 7B). The average virus titer for the
VR-2332/K07-2273 group steadily increased to 102.34 TCID50/mL at 34 dpv nd decreased o a level
similar as the homologous challenge group by 39 and 42 dpv. However, the average virus titer for
the K08-1054/K 7-2273 group increased to 102.2 TCID50/mL at 31 dpv, was constant until 39 dpv,
and decreased to 100.92 TCID50/mL at 42 dpv.
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There were no  significant differences  in  gross  or microscopic  lung  lesion  scores  among  the 
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Figure 7. The levels of viremia after virus challenge at 28, 31, 39 and 42 dpv. Serum virus
titers of K08-1054-challenged groups at 28, 31, 34, 39, and 42 dpv (A) and serum virus titers of
K07-2273-challenged groups at 28, 31, 34, 39, and 42 dp ( ). ir s titers were calculated based
on the standar curve of threshold cycle number plott t the known virus iter of VR-2332.
The bars rep sent the means, and the er or bars repre t ndard e rors of the mean (SEM).
Bars showing different lett rs epres nt values ignificantly dif ere t ther (p < 0.05).
3.5. Pathology and Viral Load in Lungs
There were no significant differences in gross or microscopic lung lesion scores among the groups
challenged with K08-1054 or K07-2273 (Figure 8). To obtain better insight regarding viral clearance from
the pigs’ bodies, the residual viral load in the lungs was determined after euthanizing all of the pigs at
42 dpv. Among the groups challenged with K08-1054, only CV/K08-1054 exhibited significantly
lower viral loads in the lung compared with the lung viral load observed in Mock/K08-1054.
The mean virus titer in the lungs of CV/K08-1054 pigs was even lower than the viral load (101.73
TCID50/mL) in the lungs of the K08-1054-homologous group (Figure 9A). The other heterologous
groups, VR-2332/K08-1054 and K07-2273/K08-1054, had mean virus titers of 102.07 TCID50/mL
and 101.96 TCID50/mL, respectively, whereas the mock-treated group had the highest viral load
in the lungs, 102.55 TCID50/mL. The mean virus titers in the lungs of all of the heterologous
groups (K08-1054/K07-2273, VR-2332/K07-2273, and CV/K07-2273) challenged with K07-2273 were
significantly lower than the mean virus titer in Mock/K07-2273, whereas the K07-2273 homologous
group xhibited a rel ti ely higher residual viral lu g load of 102.04 TCID50/mL (Figure 9B). A very
high residual viral load was also observed in the lungs of the mock-treated group, with a titer of 104.28
TCID50/mL.



















































Figure  8.  Evaluation  of  gross  and  microscopic  lung  lesions  in  pigs  at  42  dpv.  Gross  (A)  and 





































in  the  lungs  of  K08‐1054‐challenged  groups  at  42  dpv  (A).  Residual  viral  load  in  the  lungs  of   
K07‐2273‐challenged groups at 42 dpv (B). The virus  titers were calculated based on  the standard 




Current MLVs  provide  effective  protection  against  homologous  challenges  but  lack  proper 
cross‐protection  against  heterologous  challenges  [28].  Therefore,  several  reverse  genetics‐based 
PRRSV chimeras have been constructed and evaluated for their enhanced cross‐protection range in 

























































Figure 8. Evaluation of gross and microsco ic l ng lesions in pigs at 42 dpv. Gross (A) and
microsc pic (B) lung scores wer recorded after necrops . scores were plotted as the mean




















































Figure  8.  Evaluation  of  gross  and  icroscopic  lung  lesions  in  pigs  at  42  dpv.  ross  ( )  and 




































in  the  lungs  of  K08‐1054‐challenged  groups  at  42  dpv  ( ).  Residual  viral  load  in  the  lungs  of   
K07‐2273‐challenged groups at 42 dpv (B). The virus  titers  ere calculated based on  the standard 
curve  of  the  cycle  threshold nu ber plotted  against  the  kno n virus  titer  of VR‐2332. The  bars 
represent the  eans, and the error bars represent the standard error of the  ean (SE ). Bars  ith 
different letters depict values significantly different fro  each other (p < 0.05). 
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Figure 9. Quantification of resi iral lung load in challenged pigs at 42 dpv. Residual viral
load in the lungs of K08-1054-challenged groups at 42 dpv (A); Residual viral load in the lungs of
K07-2273-challenged groups at 42 dpv (B). The virus titers were calculated based on the stand rd curve
of the cycle thr shold number plotted against the known virus titer of VR-2332. The bars represent the
means, and the error bars represent the standard error of the mean (SEM). Bars with different letters
depict values significantly different from each other (p < 0.05).
4. Discussion
Current MLVs provide effective protection against homologous challenges but lack proper
cross-protection against heterologous challenges [28]. Therefore, several reverse genetics-based PRRSV
chimeras have been constructed and evaluated for their enhanced cross-protection range in previous
studies. A recent study has demonstrated that chimeric PRRS viruses harboring mixed structural genes
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from two different PRRSV strains can provide protection against both donor viruses [29]. A study has
also reported a cross-neutralizing antibody response from a PRRSV chimera engineered to contain
Korean strain-specific (LMY) structural genes in an FL12 backbone [30]. However, it has not been
further evaluated in pigs. Moreover, the presence of single, strain-specific neutralizing epitopes in
a PRRSV might limit its cross-protection against genetically diverse PRRSVs [31]. Another study
demonstrated the construction of structural genes-shuffled chimeric PRRSVs, and one chimera and
its parental strain were observed to offer partial cross-protection in pigs [32]. Although the random
shuffling of structural genes increases the heterogeneity of neutralizing epitopes in the resulting
PRRSV construct, the significance of structural proteins from different PRRSV strains and their
proper frame/order cannot be neglected when constructing an organized vaccine platform. Recently,
a new study demonstrated strong heterologous protection conferred by a synthetic PRRSV construct
with a consensus sequence obtained from the whole-genome sequence alignment of 59 different
PRRSVs [33]. Although it might be an efficient approach to broaden cross-protection against various
PRRSV strains, genome-wide sequence manipulations along with an inability to include or exclude
immunemodulatory sequences might render it a less effective platform for vaccine development.
Due to these shortcomings, it becomes imperative to construct an organized and simple PRRSV vaccine
platform that can be easily manipulated into a region or farm-specific vaccine with a backbone of
highly immunogenic PRRSV strains containing overlapping ORFs 3–4 and heterodimer-coding ORFs
5–6 from two different field isolates. Because the higher immune induction of ORFs 1a and 7 from
FL12 was demonstrated in our previous study [34], FL12 was used as a backbone to construct a
chimeric virus containing ORFs 3–4 and ORFs 5–6 from two Korean strains (K08-1054 and K07-2273,
respectively), and evaluated for cross-protective efficacy in pigs.
One of the major challenges to PRRS vaccinology is that various PRRSV strains induce different
levels of SVN antibodies, even against homologous virus [17], which was also evident in this study
among the PRRVs evaluated for SVN antibody titers at 21 dpv. In this study, CV-vaccinated pigs
displayed high SVN antibody titers of 1:14 ± 9.1 and 1:56 ± 36.6 against K08-1054 and K07-2273,
respectively; besides exhibiting a significant reduction in viremia compared with the mock groups at
42 dpv. This specific result agrees with a previous report demonstrating that an SVN antibody titer of
1:8 was sufficient to block viremia in PRRS-infected pigs [35]. Moreover, to attain sterilizing immunity
against PRRS infection, a vaccine should induce SVN antibodies to a titer of 1:32, as concluded in
previous studies [35,36]. The results of this study demonstrated that 50% of pigs vaccinated with CV
exhibited an SVN antibody titer of ≥1:32 against the Korean strains.
Cross-neutralization between various PRRSV strains is believed to be dependent on the
homologies of the structural proteins (ORFs 2–6) [22,37–45]. This observation agrees with this study,
in which higher SVN antibody induction was seen at 42 dpv in CV/K08-1054 and CV/K07-2273 against
K08-1054 and K07-2273, respectively, compared with the other groups. The reason for the higher SVN
antibody induction in these CV groups might be due to the ORFs 3–4 and ORFs 5–6 from K08-1054 and
K07-2273, respectively [22,37–45]. Notably, a major role for ORFs 5–6 in virus neutralization has been
examined in previous studies [10,39,44,46–50], which might explain the high SVN antibody induction
in CV/K07-2273 against K07-2273. However, in this study, CV/K07-2273 exhibited nine-fold higher
SVN antibody titers against K07-2273 compared with the antibody titers induced in the homologous
group (K07-2273/K07-2273), indicating a possible role for the CV backbone in SVN antibody induction.
It has been previously demonstrated that JA142, which is highly homologous to FL12, the backbone
virus for CV, induced high levels of SVN antibody compared with other PRRSV strains [17]. However,
the association between SVN antibody induction and viremia prevention in PRRS infection is still
debatable [51], as some studies suggest no association between PRRSV-induced SVN antibody titer
and viremia level in PRRS-infected pigs [35,52–54]. These observations are consistent with the present
study. CV exhibited efficient viremia reduction and high SVN antibody induction after vaccination and
challenge, whereas other PRRSVs (K08-1054, K07-2273, and VR-2332) induced lower SVN antibody
titers despite fair reduction of viremia.
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To date, the cell-mediated immune response elicited by PRRSV is unclear. Previous reports
have demonstrated that PRRSV caused immunosuppression by upregulating IL-10, which in turn
inhibited the expression of the cytokines responsible for viral clearance (IFN-α, IFN-γ, IL-12,
and TNF-α) [54,55]. In this study, CV-vaccinated pigs presented a different scenario compared to other
groups, with relatively lower IL-10, higher IFN-γ and higher TNF-α mRNA levels in PBMC cultures at
21 dpv. Simultaneously, higher TNF-α and IL-12 protein expression in PBMC supernatants suggests
that CV induced the least immunosuppressive effect among all of the vaccines tested. These results
are also consistent with a study in which high and spontaneous IFN-γ production in cultures was
observed in unstimulated pig PBMCs inoculated with an inactivated vaccine [56]. Moreover, the higher
TNF-α and IFN-γ expression in CV-vaccinated pigs in this study was also associated with reduction of
viremia at 21 dpv, which is in agreement with earlier studies that demonstrated roles for TNF-α and
IFN-γ in the inhibition of PRRSV replication [57,58].
Chimeric PRRS viruses used in previous animal studies have not been shown to affect the
body weight of infected pigs [20,59], which is consistent with this study, in which CV-vaccinated
pigs displayed fair weight gain at 25 dpv compared to the other vaccinated groups. However,
the CV-vaccinated groups exhibited similar or relatively higher gross lung pathology compared
with the other vaccinated groups despite displaying significantly higher SVN antibodies against
homologous virus, cross-neutralization titers and viremia reduction that were comparable to those
observed in homologous-challenged Korean strains, with significantly lower IL-10 expression in
PBMCs at 21 dpv. This observation is in agreement with a recent study that demonstrated an enhanced
adaptive immune response and virus clearance coupled with increased gross pathology in pigs that
were experimentally infected with an SU-1 bell strain of type-I PRRSV [60].
5. Conclusions
In summary, CV-vaccinated pigs exhibited reduced viremia and viral lung loads against
challenges with two heterologous viruses, which induced relatively higher levels of SVN antibody and
cell-mediated immune responses compared with the other vaccinated groups. The study also suggests
that the cross-protective capacity of CV tested against K08-1054 and K07-2273 might be facilitated due
not only to the presence of structural proteins from these virus strains but also by an immunogenic
pFL-12 backbone. Therefore, this study opens new possibilities for broadly effective vaccines against
various PRRSV strains.
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